Search results
Your search for XIST returned no results
Showing 1516 to 1530 of 1556 results for list
Showing 1516 to 1530 of 1556 results for list
Preparing for the next breakthroughs in liver disease treatments
With no licensed treatments for MASH, a serious liver condition affecting 3 million in the UK, NICE has co-developed a framework with patients, clinicians, and industry to accelerate access to promising new medicines.
For more than 25 years NICE has helped practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
Learn about our role in the new international Health Economics Methods Advisory (HEMA) and its ambitions to make a real difference to patients around the world.
Our chief executive, Dr Sam Roberts, welcomes the government's 10 Year Plan for healthcare
The government's 10 Year Plan marks a pivotal moment for healthcare and strengthens NICE’s role.
Same time decisions on licensing and value - what pharmaceutical companies need to know
Learn how NICE and MHRA are launching an aligned pathway to accelerate patient access to medicines and provide a more efficient route for industry.
The new approach puts HealthTech on equal footing with medicines, ensuring innovations like wearable diabetes monitors and AI diagnostics reach patients faster and more consistently across the NHS.
Final decision on cerliponase alfa for Batten disease treatment confirmed
In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid lipofuscinosis type 2 (CLN2), a rare and life-limiting form of Batten disease.
AI skin cancer detection system gets green light for conditional NHS use
An artificial intelligence system for potential skin cancer has been conditionally recommended for use in the NHS for the next three years while further evidence is collected.
First-ever NHS treatment approved for advanced Hodgkin lymphoma
New combination therapy offers hope to 800 people annually with late-stage blood cancer.
Annual BMI checks recommended for adults with long-term conditions
We've published a draft quality standard calling for yearly BMI and waist-to-height measurements to help prevent weight-related complications.
First licensed treatment for ultra-rare immune disorder recommended
Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) licensed for use in the NHS in England.
NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in people aged 2 and over with severe haemophilia A.
Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
We've recommended an innovative one-off cell therapy that could give hundreds of lymphoma patients precious extra time with loved ones.
NICE describes how weight loss drug tirzepatide will be rolled out
The medication will initially be offered only to those people with the highest clinical needs.
NICE recommends 8 digitally enabled therapies to treat depression and anxiety
Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by NICE in draft guidance.